Lakefront Biotherapeutics N.V.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
LKFT · Price history
Price at last available close
$32.08
+$2.56 (+8.67%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Lakefront Biotherapeutics N.V.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
How they make money
Lakefront Biotherapeutics is a biotechnology company that generates revenue primarily through research and development collaborations, licensing agreements for its proprietary drug candidates, and product sales. The company focuses on discovering and developing small molecule and antibody therapies in the fields of immunology and oncology, often partnering with larger pharmaceutical entities to fund clinical trials and commercialize its pipeline.
Products & services
The company's pipeline includes GLPG3667 for inflammatory diseases, GLPG5101 and GLPG5301 as CAR-T cell therapy candidates for oncology, and various other small molecule and antibody programs.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
The company's revenue is highly concentrated due to its reliance on a limited number of strategic collaboration and licensing partners, as disclosed in the 2025 Annual Report.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — Various unnamed third-party organizations providing clinical trial management and research support services.Source
- Contract Manufacturing Organizations (CMOs) — Unnamed third-party manufacturers responsible for the production of clinical trial materials and drug candidates.Source
Business relationships & partnerships
- Gilead Sciences — A long-standing strategic collaboration involving the development and commercialization of various pipeline assets and research programs.Source
Competitors
Strengths
Company-specific research
Questions worth answering for LKFT
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving LKFT's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can LKFT fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is LKFT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is LKFT's valuation discount tied to a temporary concern or to a longer-term business risk?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of LKFT's score?
Essential Investment Snapshot
Market Cap
$2.10B
P/E Ratio
2.8
EPS
$10.26
52-Week High
$37.78
52-Week Low
$25.68
Beta
0.12
Analyst Target
$35.50
Shares Outstanding
65.9M
Total Debt
$7.2M
Dividend
No current dividend
Liquidation Value / Share
$56.14
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for LKFT
Detected from reported data — verify before acting.M&A headline · Sep 29, 2026
Acquisition of Own Shares — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireM&A headline · Sep 22, 2026
Acquisition of Own Shares — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireM&A headline · Sep 15, 2026
Acquisition of Own Shares — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireM&A headline · Sep 8, 2026
Acquisition of Own Shares — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireM&A headline · Sep 1, 2026
Acquisition of Own Shares — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on LKFT.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Robust proprietary drug discovery platform.
- +Strong cash position to support R&D activities.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on strategic partners for commercialization and funding.
- −Inherent risks and uncertainties in clinical trial outcomes and regulatory approvals.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Review model assumptionsThis model estimate is more than three times the share price.
This is a formula-based estimate, not a verified fair value or price target. Check the earnings and growth assumptions.
Stored EPS: $10.26 · Growth assumption: 15.0% · Earnings multiplier: 38.5×.
Current Price
$32.08
Model Intrinsic Value
$394.95
Difference
−$362.87
-91.9% vs IV
Margin of Safety
91.9%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +303.5%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $1.12B | $1.26B | $312.6M | $271.9M | ···· | ···· |
| Cost of Revenue | $57.5M | $33.7M | $39.5M | $0.00 | ···· | ···· |
| Gross Profit | $1.07B | $1.23B | $273.1M | $271.9M | ···· | ···· |
| Research & Development | $269.8M | $521.0M | $380.4M | $273.6M | ···· | ···· |
| SG&A Expenses | $122.2M | $127.0M | $109.9M | $106.9M | ···· | ···· |
| Operating Expenses | $374.1M | $659.0M | $486.6M | $371.9M | ···· | ···· |
| EBITDA | $677.6M | $407.1M | $49.1M | $57.9M | ···· | ···· |
| Operating Income | $691.7M | $568.6M | -$213.6M | -$100.1M | ···· | ···· |
| Interest Expense | $2.5M | $2.5M | $1.0M | $2.0M | ···· | ···· |
| Income Before Tax | $655.1M | $341.2M | -$3.5M | $6.4M | ···· | ···· |
| Income Tax Expense | -$18.9M | -$21.1M | -$2.0M | $10.9M | ···· | ···· |
| Net Income | $676.6M | $363.9M | $84.0M | $240.1M | ···· | ···· |
| Basic EPS | $10.26 | $5.52 | $1.27 | $3.64 | ···· | ···· |
| Basic Shares | 73.71M | 65.90M | 66.14M | 65.88M | ···· | ···· |
| Diluted Shares | 66.93M | 65.90M | 66.14M | 65.88M | ···· | ···· |
Earnings Summary
Revenue
$13.7M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.03
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-24.7%
Cash Change
+89.6%
Margin Change
+179.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included cash levels, debt levels, net income margin. Pressure indicators included revenue growth, EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue declined 81.4%. EPS declined 101.8%. Cash increased 89.6%. Total debt declined 24.7%. Net income margin improved by 179.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyRumor Mill · LKFT
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial